IceCure Medical jumps on U.S. ProSense install base growth after FDA clearance
IceCure Medical shares surged more than threefold late Wednesday morning on Nasdaq. The Israeli medical-device company said U.S. commercial adoption of its ProSense cryoablation system for breast cancer climbed sharply since it received FDA clearance last year. Cryoablation is a method that destroys tissue by freezing. The stock climbed $5.04 to $7.17, after touching $9.45 earlier in the session. That jump stood out as Wall Street stayed mostly quiet with small gains; Reuters said the Dow added 0.15%, the S&P 500 edged up 0.11%, and the Nasdaq gained 0.35% at 9:41 a.m. ET.